6.18
price down icon5.36%   -0.35
after-market Handel nachbörslich: 6.23 0.05 +0.81%
loading
Schlusskurs vom Vortag:
$6.53
Offen:
$6.17
24-Stunden-Volumen:
43,278
Relative Volume:
0.46
Marktkapitalisierung:
$95.50M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-14.88M
KGV:
-6.3061
EPS:
-0.98
Netto-Cashflow:
$-10.29M
1W Leistung:
+17.49%
1M Leistung:
-5.65%
6M Leistung:
-31.03%
1J Leistung:
-26.69%
1-Tages-Spanne:
Value
$6.04
$6.58
1-Wochen-Bereich:
Value
$5.0595
$7.05
52-Wochen-Spanne:
Value
$4.65
$10.24

Coya Therapeutics Inc Stock (COYA) Company Profile

Name
Firmenname
Coya Therapeutics Inc
Name
Telefon
650.739.3939
Name
Adresse
12645 MEMORIAL DR., SUITE F1 #305, HOUSTON
Name
Mitarbeiter
8
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
COYA's Discussions on Twitter

Vergleichen Sie COYA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
COYA
Coya Therapeutics Inc
6.18 95.50M 0 -14.88M -10.29M -0.98
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

Coya Therapeutics Inc Stock (COYA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-12-04 Eingeleitet D. Boral Capital Buy

Coya Therapeutics Inc Aktie (COYA) Neueste Nachrichten

pulisher
11:27 AM

Coya Therapeutics: Treg Proof-Of-Concept Continues With Interim FTD Data Release - Seeking Alpha

11:27 AM
pulisher
03:33 AM

Coya Therapeutics advances COYA 303 for inflammatory diseases - MSN

03:33 AM
pulisher
Apr 24, 2025

Coya Therapeutics Announce Positive Interim Result from - openPR.com

Apr 24, 2025
pulisher
Apr 24, 2025

Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia – EventsNewsAsia.com - eventsnewsasia.com

Apr 24, 2025
pulisher
Apr 24, 2025

Biotech Discovers Revolutionary Immunotherapy in Houston - streetwisereports.com

Apr 24, 2025
pulisher
Apr 24, 2025

Coya stock in focus after interim results for dementia drug - Seeking Alpha

Apr 24, 2025
pulisher
Apr 24, 2025

Coya Reports Positive Data From Proof Of Concept Open-label Study Of IL-2 And CTLA4-Ig Combo In FTD - Nasdaq

Apr 24, 2025
pulisher
Apr 24, 2025

Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia - businessnews.ph

Apr 24, 2025
pulisher
Apr 24, 2025

Coya Therapeutics Announces Positive Interim Results Of An Investigator-Initiated Open Label Study With Low-Dose IL-2 And CTLA4-Ig Combination Treatment In Five Patients With Mild To Moderate Frontotemporal Dementia - marketscreener.com

Apr 24, 2025
pulisher
Apr 24, 2025

Revolutionary Frontotemporal Dementia Treatment Prevents Cognitive Decline in All Trial Patients - Stock Titan

Apr 24, 2025
pulisher
Apr 24, 2025

Coya Therapeutics (NASDAQ:COYA) Earns Buy Rating from D. Boral Capital - Defense World

Apr 24, 2025
pulisher
Apr 23, 2025

Wall Street Analysts See a 144.73% Upside in Coya Therapeutics, Inc. (COYA): Can the Stock Really Move This High? - Yahoo Finance

Apr 23, 2025
pulisher
Apr 22, 2025

AI in Clinical Trials Market Growth 2025: Trends, Consumer - openPR.com

Apr 22, 2025
pulisher
Apr 22, 2025

Coya Therapeutics (NASDAQ:COYA) Trading 8.6% Higher – What’s Next? - Defense World

Apr 22, 2025
pulisher
Apr 21, 2025

Coya Therapeutics, Inc. Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death) - marketscreener.com

Apr 21, 2025
pulisher
Apr 20, 2025

(COYA) Long Term Investment Analysis - news.stocktradersdaily.com

Apr 20, 2025
pulisher
Apr 11, 2025

Is Coya Therapeutics (COYA) the Top Healthcare Stock to Buy According to Billionaire David Einhorn? - Yahoo Finance

Apr 11, 2025
pulisher
Apr 10, 2025

Coya Therapeutics stock hits 52-week low at $4.72 - Investing.com Australia

Apr 10, 2025
pulisher
Apr 09, 2025

Coya Therapeutics stock hits 52-week low at $4.72 By Investing.com - Investing.com Canada

Apr 09, 2025
pulisher
Apr 02, 2025

Exosomes Pipeline 2025: MOA and ROA Insights, Clinical Trials - openPR.com

Apr 02, 2025
pulisher
Apr 01, 2025

Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025 - The Joplin Globe

Apr 01, 2025
pulisher
Mar 31, 2025

GMP Production of Exosomes Slated for Later This Year - streetwisereports.com

Mar 31, 2025
pulisher
Mar 29, 2025

D. Boral Capital Reiterates Buy Rating for Coya Therapeutics (NASDAQ:COYA) - Defense World

Mar 29, 2025
pulisher
Mar 28, 2025

Biotech Advances Revolutionary Treatment for Neurodegenerative Diseases - Streetwise Reports

Mar 28, 2025
pulisher
Mar 28, 2025

What is Chardan Capital’s Forecast for COYA FY2025 Earnings? - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

What Makes Coya Therapeutics, Inc. (COYA) a New Buy Stock - Yahoo Finance

Mar 27, 2025
pulisher
Mar 27, 2025

Wall Street Analysts Think Coya Therapeutics, Inc. (COYA) Could Surge 149.62%: Read This Before Placing a Bet - Yahoo Finance

Mar 27, 2025
pulisher
Mar 27, 2025

Are Medical Stocks Lagging Auna S.A. (AUNA) This Year? - Yahoo

Mar 27, 2025
pulisher
Mar 26, 2025

Coya Therapeutics advances Treg exosome production By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

Coya Therapeutics advances Treg exosome production - Investing.com India

Mar 26, 2025
pulisher
Mar 26, 2025

Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program - Joplin Globe

Mar 26, 2025
pulisher
Mar 26, 2025

Revolutionary Treg Exosome Treatment Could Transform Neurodegenerative Disease Therapy - Stock Titan

Mar 26, 2025
pulisher
Mar 25, 2025

Agitation in Alzheimer's Disease Market: Analysis - openPR.com

Mar 25, 2025
pulisher
Mar 24, 2025

(COYA) Trading Report - news.stocktradersdaily.com

Mar 24, 2025
pulisher
Mar 22, 2025

Coya Therapeutics (NASDAQ:COYA) Earns Buy Rating from Chardan Capital - Defense World

Mar 22, 2025
pulisher
Mar 21, 2025

Coya Therapeutics Reports 2024 Financial Results and Progress - TipRanks

Mar 21, 2025
pulisher
Mar 20, 2025

Coya Therapeutics to Present ALS Clinical Study Data for its Investigational Biologic Combination at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference. - Business Wire

Mar 20, 2025
pulisher
Mar 20, 2025

Coya Therapeutics (NASDAQ:COYA) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance

Mar 20, 2025
pulisher
Mar 20, 2025

BTIG maintains Buy on Coya Therapeutics, target at $15 By Investing.com - Investing.com Canada

Mar 20, 2025
pulisher
Mar 19, 2025

Coya Therapeutics’ (COYA) Buy Rating Reaffirmed at D. Boral Capital - Defense World

Mar 19, 2025
pulisher
Mar 18, 2025

Coya Therapeutics Reports 2024 Financial Results and Updates - TipRanks

Mar 18, 2025
pulisher
Mar 18, 2025

Coya Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 18, 2025
pulisher
Mar 18, 2025

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results - Business Wire

Mar 18, 2025
pulisher
Mar 15, 2025

Coya Therapeutics, Inc. Announces Closing of $15.25 Million Initial Public Offering - Business Wire

Mar 15, 2025
pulisher
Mar 15, 2025

Coya Therapeutics Announces Closing of $26.5 Million Private Placement - Business Wire

Mar 15, 2025
pulisher
Mar 14, 2025

12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga

Mar 14, 2025
pulisher
Mar 13, 2025

Where are the Opportunities in (COYA) - Stock Traders Daily

Mar 13, 2025
pulisher
Mar 11, 2025

Coya Therapeutics (COYA) to Release Earnings on Tuesday - Defense World

Mar 11, 2025
pulisher
Mar 11, 2025

D. Boral Capital Reaffirms Buy Rating for Coya Therapeutics (NASDAQ:COYA) - The AM Reporter

Mar 11, 2025
pulisher
Mar 11, 2025

Coya Therapeutics’ (COYA) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World

Mar 11, 2025
pulisher
Mar 10, 2025

Market Watch Highlights: Coya Therapeutics Inc (COYA) Ends on an Upturn Note at 6.88 - The Dwinnex

Mar 10, 2025

Finanzdaten der Coya Therapeutics Inc-Aktie (COYA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
Kapitalisierung:     |  Volumen (24h):